Heron Therapeutics, Inc.'s ( NASDAQ:HRTX ) : Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. On 31 December 2018, the US$1.3b market-cap posted a loss of -US$178.8m for its most recent financial year. As path to profitability is the topic on HRTX's investors mind, I've decided to gauge market sentiment. In this article, I will touch on the expectations for HRTX's growth and when analysts expect the company to become profitable.